E2F-1 directly regulates thrombospondin 1 expression

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Ji, Wei ^a   Zhang, Wei ^a   Xiao, Wuhan ^a  

^a INSTITUTE OF HYDROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RETINOBLASTOMA PROTEIN; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR E2F1; DNA;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; IN VIVO STUDY; NORTHERN BLOTTING; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TRANSCRIPTION INITIATION SITE; UPREGULATION; CELL LINE; GENE SILENCING; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROTEIN BINDING; WESTERN BLOTTING;

BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DNA; E2F1 TRANSCRIPTION FACTOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER; THROMBOSPONDIN 1;

EID: 78149426172     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013442     Document Type: Article

References (47)

1. Bein K, Simons M (2000) Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275: 32167-32173.
2. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, et al. (1997) CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138: 707-717.
3. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, et al. (2007) Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP- 1). J Cell Physiol 210: 807-818.
4. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, et al. (2007) Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 282: 15404-15415.
5. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, et al. (2006) CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281: 26069-26080.
6. Krutzsch HC, Choe BJ, Sipes JM, Guo N, Roberts DD (1999) Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1. J Biol Chem 274: 24080-24086.
7. Li Z, Calzada MJ, Sipes JM, Cashel JA, Krutzsch HC, et al. (2002) Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol 157: 509-519.
8. Moodley Y, Rigby P, Bundell C, Bunt S, Hayashi H, et al. (2003) Macrophage recognition and phagocytosis of apoptotic fibroblasts is critically dependent on fibroblast-derived thrombospondin 1 and CD36. Am J Pathol 162: 771-779.
9. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P (2008) Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 19: 563-571.
10. Pallero MA, Elzie CA, Chen J, Mosher DF, Murphy-Ullrich JE (2008) Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. Faseb J 22: 3968-3979.
11. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, et al. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 87: 6624-6628.
12. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584.
13. Liu P, Wang Y, Li YH, Yang C, Zhou YL, et al. (2003) Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res 27: 701-708.
14. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, et al. (2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 98: 12485-12490.
15. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, et al. (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6: 41-48.
16. Li K, Yang M, Yuen PM, Chik KW, Li CK, et al. (2003) Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3. Int J Mol Med 12: 995-1001.
17. Sheibani N, Frazier WA (1996) Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett 107: 45-52.
18. Brechot N, Gomez E, Bignon M, Khallou-Laschet J, Dussiot M, et al. (2008) Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice. PLoS One 3: e3950.
19. Bruel A, Touhami-Carrier M, Thomaidis A, Legrand C (2005) Thrombospondin-1 (TSP-1) and TSP-1-derived heparin-binding peptides induce promyelocytic leukemia cell differentiation and apoptosis. Anticancer Res 25: 757-764.
20. Kyriakides TR, Maclauchlan S (2009) The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J Cell Commun Signal 3: 215-225.
21. Agah A, Kyriakides TR, Lawler J, Bornstein P (2002) The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double- TSP1/TSP2-null mice. Am J Pathol 161: 831-839.
22. DiPietro LA, Nissen NN, Gamelli RL, Koch AE, Pyle JM, et al. (1996) Thrombospondin 1 synthesis and function in wound repair. Am J Pathol 148: 1851-1860.
23. Streit M, Velasco P, Riccardi L, Spencer L, Brown LF, et al. (2000) Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. Embo J 19: 3272-3282.
24. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, et al. (2001) PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A 98: 4622-4627.
25. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA (2003) Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3: 219-231.
26. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, et al. (2001) Thrombospondin-1 gene expression affects survival and tumor spectrum of p53- deficient mice. Am J Pathol 159: 1949-1956.
27. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, et al. (2009) Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 139: 380-392.
28. Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, et al. (2005) Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 120: 421-433.
29. Xu J, Xiao N, Xia J. Thrombospondin 1 accelerates synaptogenesis in hippocampal neurons through neuroligin 1. Nat Neurosci 13: 22-24.
30. Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N (2003) Thrombospondin-1- deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn 228: 630-642.
31. Zhou J, Feng X, Ban B, Liu J, Wang Z, et al. (2009) Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation. J Biol Chem 284: 19142-19152.
32. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30: 41-47.
33. Eguchi M, Eguchi-Ishimae M, Greaves M (2005) Molecular pathogenesis of MLL-associated leukemias. Int J Hematol 82: 9-20.
34. Liu H, Takeda S, Cheng EH, Hsieh JJ (2008) Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia. Cell Cycle 7: 428-435.
35. Thirman MJ, Levitan DA, Kobayashi H, Simon MC, Rowley JD (1994) Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc Natl Acad Sci U S A 91: 12110-12114.
36. DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, et al. (2000) A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 96: 3887-3893.
37. Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553.
38. Liu K, Luo Y, Lin FT, Lin WC (2004) TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev 18: 673-686.
39. Helin K, Wu CL, Fattaey AR, Lees JA, Dynlacht BD, et al. (1993) Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev 7: 1850-1861.
40. Attwooll C, Lazzerini Denchi E, Helin K (2004) The E2F family: specific functions and overlapping interests. Embo J 23: 4709-4716.
41. Chen HZ, Tsai SY, Leone G (2009) Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 9: 785-797.
42. Harbour JW, Dean DC (2000) The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14: 2393-2409.
43. Frolov MV, Dyson NJ (2004) Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 117: 2173-2181.
44. van den Heuvel S, Dyson NJ (2008) Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol 9: 713-724.
45. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10: 699-703.
46. Burkhart DL, Sage J (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8: 671-682.
47. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.